Kymera Investor Day Presentation Deck
Our 5-year Vision: Where Kymera Will Be in 2026
A fully-integrated biotech company with a disease
KYMERA and technology agnostic pipeline and capabilities
Path to NDA
for at least 1
program
Disease and
technology-
agnostic pipeline
and capabilities
At least 8 clinical
stage programs
across different
development stages
and disease areas
Expand technology
platform to
wholistically
address undrugged
proteome
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
Pipeline
positioned to
deliver at least 1
new IND per year
Continued
commitment to
innovation and first-
in-class science and
medicines
KYMERA R&D DAY - December 16th, 2021
Clinical proof-of-concept
established in tissue-
selective/restricted
degradation and
undrugged targets
Commercial
organization build up
in progress
PAGE 102View entire presentation